In contrast, in a small study with n = 31 NSCLC patients treated with pembrolizumab monotherapy, the authors found that serum CRP levels at pre-treatment were not predictive, but increase of serum CRP at 6 weeks after anti-PD-1 therapy was predictive of clinical benefit [18]. This evidence concerns the gene CRP and non-small cell lung carcinoma.